
    
The genomic variant c.907A>G p.Thr303Ala rs876660744 is located in the CDH1 gene, which encodes E-cadherin, a protein that plays a crucial role in cell-cell adhesion and maintenance of epithelial cell polarity. E-cadherin is a key component of adherens junctions, which are essential for the establishment of the epithelial barrier function and for the prevention of invasive and metastatic behavior of epithelial cells. The CDH1 gene is therefore implicated in the regulation of tissue architecture and cellular signaling pathways that control cell proliferation and differentiation.The c.907A>G p.Thr303Ala variant results in the substitution of threonine with alanine at position 303 of the E-cadherin protein. This missense change is located in the extracellular domain of E-cadherin, which is important for its adhesive functions and for mediating homophilic calcium-dependent interactions between E-cadherin molecules on adjacent cells.ClinVar submissions for this variant include 2 benign and 3 with uncertain significance, indicating that there is some discrepancy in the interpretation of its clinical significance. The benign submissions suggest that this variant may not have a deleterious effect on the protein function or may represent a rare benign polymorphism in the population. However, the uncertain significance submissions indicate that there is not enough evidence to conclusively determine the impact of this variant on the protein function and its association with disease.In summary, the c.907A>G p.Thr303Ala rs876660744 variant in the CDH1 gene is a missense change with conflicting interpretations of its clinical significance. The variant's effect on E-cadherin's function and its potential association with disease remain to be fully elucidated through further functional studies and accumulation of clinical data.

ゲノム変異 c.907A>G p.Thr303Ala rs876660744 は、E-カドヘリンをコードする **CDH1** 遺伝子に位置しています。E-カドヘリンは、細胞間接着および上皮細胞の極性維持において重要な役割を果たすタンパク質です。E-カドヘリンは接着結合（アドヘレンスジャンクション）の主要な構成要素であり、これらの結合は上皮バリア機能の確立や、上皮細胞の浸潤性および転移性の行動を防ぐために不可欠です。そのため、**CDH1** 遺伝子は組織構造の調節や、細胞増殖および分化を制御する細胞シグナル伝達経路に関与しています。

c.907A>G p.Thr303Ala 変異は、E-カドヘリンタンパク質の303番目の位置でスレオニン（Thr）がアラニン（Ala）に置換される結果をもたらします。このミスセンス変異は、E-カドヘリンの細胞外ドメインに位置しており、このドメインは接着機能や隣接する細胞上のE-カドヘリン分子間のホモフィリックなカルシウム依存性相互作用を媒介するために重要です。

この変異に関するClinVarの提出データには、2件の「良性（benign）」と3件の「意義不明（uncertain significance）」が含まれており、その臨床的意義の解釈において矛盾があることを示しています。「良性」とされた提出データは、この変異がタンパク質機能に有害な影響を及ぼさない、または集団内で稀な良性多型を表している可能性を示唆しています。一方、「意義不明」とされた提出データは、この変異がタンパク質機能に与える影響や疾患との関連性を決定するための十分な証拠がまだ存在しないことを示しています。

まとめると、**CDH1** 遺伝子の c.907A>G p.Thr303Ala rs876660744 変異は、臨床的意義に関する解釈が矛盾しているミスセンス変異です。この変異がE-カドヘリンの機能に与える影響や疾患との潜在的な関連性については、さらなる機能的研究や臨床データの蓄積を通じて完全に解明される必要があります。
    
## References
- [1] Zhang J et al. (2018). "Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance." Nature, 553(7686) [PubMed](https://pubmed.ncbi.nlm.nih.gov/29160310/)
- [2] Arasu UT et al. (2020). "HAS3-induced extracellular vesicles from melanoma cells stimulate IHH mediated c-Myc upregulation via the hedgehog signaling pathway in target cells." Cellular and molecular life sciences : CMLS, 77(20) [PubMed](https://pubmed.ncbi.nlm.nih.gov/31820036/)
- [3] Casciano JC et al. (2020). "MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer." British journal of cancer, 122(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/31942031/)
- [4] Rajbhandari N et al. (2023). "Single-cell mapping identifies MSI(+) cells as a common origin for diverse subtypes of pancreatic cancer." Cancer cell, 41(11) [PubMed](https://pubmed.ncbi.nlm.nih.gov/37802055/)
- [5] Chen CH et al. (2014). "Cdc6 cooperates with c-Myc to promote genome instability and epithelial to mesenchymal transition EMT in zebrafish." Oncotarget, 5(15) [PubMed](https://pubmed.ncbi.nlm.nih.gov/25051368/)
- [6] Su Y et al. (2018). "Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals." Genes & development, 32(21-22) [PubMed](https://pubmed.ncbi.nlm.nih.gov/30366908/)
- [7] Thibodeaux CA et al. (2009). "Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant." Breast cancer research and treatment, 116(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/18642118/)
- [8] Cuevas IC et al. (2019). "Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition." Proceedings of the National Academy of Sciences of the United States of America, 116(51) [PubMed](https://pubmed.ncbi.nlm.nih.gov/31772025/)
- [9] Paul S et al. (2024). "NAK-associated protein 1/NAP1 activates TBK1 to ensure accurate mitosis and cytokinesis." The Journal of cell biology, 223(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38059900/)
- [10] Parang B et al. (2017). "BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis." Gut, 66(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/28389570/)
- [11] Wu L et al. (2019). "Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC." Cancer research, 79(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/30733194/)
- [12] Fur GM et al. (2024). "Applied models and molecular characteristics of small cell lung cancer." Pathology oncology research : POR, 30() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38711976/)
- [13] Ohtsuka S et al. (2015). "LIF signal in mouse embryonic stem cells." JAK-STAT, 4(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/27127728/)
- [14] Tanioka M et al. (2018). "Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer." Genome medicine, 10(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/30497520/)
- [15] Wong MM et al. (2021). "Transcription Factor AP4 Mediates Cell Fate Decisions: To Divide, Age, or Die." Cancers, 13(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/33567514/)

    
## ClinVar Submissions
- **[RCV001018797](https://www.ncbi.nlm.nih.gov/clinvar/RCV001018797/)**: Hereditary cancer-predisposing syndrome
- **[RCV000214986](https://www.ncbi.nlm.nih.gov/clinvar/RCV000214986/)**: not provided
- **[RCV000691264](https://www.ncbi.nlm.nih.gov/clinvar/RCV000691264/)**: Hereditary diffuse gastric adenocarcinoma
- **[RCV000218776](https://www.ncbi.nlm.nih.gov/clinvar/RCV000218776/)**: Hereditary cancer-predisposing syndrome
- **[RCV000639236](https://www.ncbi.nlm.nih.gov/clinvar/RCV000639236/)**: Hereditary diffuse gastric adenocarcinoma

    